|
Friday 7 September 2018
|
|
|
12:00 - 13:15
|
Introductory Session: An ambitious agenda on cancer in Europe
|
|
In the wake of eurosceptic challenge, there is heightened impetus for the EU to ensure strong connection to the common aspirations of the citizen. Can a reenergised EU cancer agenda provide fresh demonstration of the benefits of structured cooperation between European countries? What should a more ambitious European agenda on cancer look like and consist of? What have we learned so far, and can examples from elsewhere, such as the USA’s Cancer Moonshot initiative, provide instructive lesson?
Session Co-Chairs: Dr Ian Banks and Prof Philip Poortmans
Speakers include:
Dr Vytenis Andriukaitis
EU Commissioner for Health & Food Safety
View Presentation
Her Excellency Marie-Louise Coleiro Preca (Video address)
President of Malta
View Presentation
Dr Dinah Singer
National Institute of Health, USA
View Presentation
Prof Mark Lawler
Queen's University Belfast, United Kingdom
View Presentation
Alojz Peterle MEP
President, MEPs Against Cancer
|
13:15 - 15:00
|
Outcomes Research: Adopting a 20 year mindset – the paradigm shift required
|
|
NEW HORIZON SESSION
|
|
With cancer incidence rates expected to grow by 68% worldwide between 2012 and 2030, matching the promise of new science and treatment options with continually constrained public finance points to a more value-based landscape for rewarding innovation. It is right to demand more evidence and further certainty in respect to the real life benefits and outcomes achieved by current and potential models and modes of cancer care. It is to this need that outcomes research is addressed, a branch of public health research, which studies the outcomes of the structure and processes of the health care system on the health and well-being of patients and populations.
Yet obstacles remain in the path of progress, with identifiable gaps in the data infrastructure, research landscape, and international multi-stakeholder agreement on matters such as data sharing, ownership and protection.
Prof Richard Sullivan (Session Chair)
Kings College London, United Kingdom
View Presentation
Dr Claudia Allemani
London School of Hygiene and Tropical Medicine, UK
Dr John O'Donnell
Global VP, Health Economics and Outcomes Research, Bristol-Myers Squibb, USA
View Presentation
Dr Bettina Ryll
Melanoma Patient Network Europe, Sweden
View Presentation
Assigned intervention from
Julia Levy
Collaboration for Oncology Data in Europe (CODE), United Kingdom
Dr Miroslav Mikolášik MEP
Member of ENVI Committee, European Parliament
|
15:00 - 15:30
|
Refreshment Break
|
15:30 - 17:30
|
Big Data – who’s in charge?
|
|
DEBATE SESSION |
|
Stakeholders recognise the benefits big data can bring to research and improvement of care and treatment for cancer. However its full realisation is unlikely to occur without leadership, responsibility, strategy, direction and implementation.
What aspects of leadership and responsibility appear to be presently missing in terms of bringing big data opportunities to fruition, to whom should these leadership roles be assigned, and where does accountability reside? Implicit within this discussion is considered reflection on whether the realisation of a big data-driven future in research requires the strong hand of government-led efforts, or whether responsibilities are of a more shared and distributed nature?
Prof Mark Lawler (Session Chair)
Queen's University Belfast, United Kingdom
View Presentation
View Presentation
Jan Geissler
CML Advocates Network, Germany
View Presentation
Dr Denis Lacombe
Director General, EORTC, Belgium
View Presentation
Dr Clifford Hudis
CEO, American Society of Clinical Oncology (ASCO)
View Presentation
Prof Eva Morris
University of Leeds, United Kingdom
View Presentation
|
|
|
17::30 - 17:40 |
Launch of 'A new era in Cancer Care' |
|
|
17:40 |
Welcome Reception |
|
|
Saturday 8 September 2018
|
|
|
9:00 - 10:30
|
Improving efficiency in cancer care: how can multidisciplinarity make a difference?
|
|
NEW HORIZON SESSION
|
|
-
Highlighted latest research from All.Can on patient experience and perspective in respect to inefficiency in cancer care and opportunities for improvement
-
Explored the role of multidisciplinary cancer care in addressing inefficiency in cancer care (e.g. reducing delays and unnecessary interventions, and improving outcomes)
-
Reflected on conclusions from 2018 research on waste and inefficiency in cancer care by the Swedish Institute for Health Economics (IHE)
Prof Peter Naredi (Session Chair)
View Presentation
Kathy Oliver
International Brain Tumour Alliance, UK
View Presentation
Prof Bengt Jonsson
Stockholm School of Economics, Sweden
View Presentation
Amadou Diarra
Global VP Policy Advocacy & Government Affairs, Bristol-Myers Squibb, USA
View Presentation
Dr Monica Bertagnolli
ASCO President, USA
View Presentation
Prof Hideo Baba
Japan Society of Clinical Oncology
View Presentation
|
10:30 - 11:00
|
Coffee Break |
11:00 - 12:30
|
Integration of cancer care: the essential requirements
|
|
RESOLUTION FORMING SESSION |
|
It is recognised that a multi-disciplinary and patient-centric approach is required to achieve integrated cancer care, central to attaining the best outcomes and quality of care for patients. But how do we move beyond the shared aspiration of integrated cancer care, to its real-life practice in daily reality? ECCO and primary care partner organisations have grappled with this question as part of a project to define “the essential requirements for primary care interventions throughout the cancer care pathway”. The outcomes of this work was presented at the session, before inviting participants at the Summit to help finalise consensus resolutions on the topic.
The resolutions included time-based targets for improvement, supported by assignment of responsibilities for achieving the goal, and underpinned by tools to aid implementation.
Dr Ian Banks (Session Co-Chair)
ECCO Patient Advisory Committee Chair, Belgium
View Presentation
Prof Peter Selby (Session Co-Chair)
University of Leeds, UK
View Presentation
Dr Tit Albreht
National Institute of Public Health, Slovenia
View Presentation
Prof David Weller
University of Edinburgh, UK
View Presentation
Dr Agnieszka Kolacinska
European Society of Surgical Oncology (ESSO)
View Presentation
Prof Alain Astier
European Society of Oncology Pharmacists (ESOP)
View Presentation
|
12:30 - 13:30
|
Lunch
|
13:30 -15:00
|
Quality in cancer care: how to demand it, measure it and implement it
|
|
RESOLUTION FORMING SESSION
|
|
We all want quality cancer care, but how can we describe what it consists of, acquire a reliable measure of the level of quality of cancer care being delivered, and succeed in implementing improvement?
To these three questions a range of expert contributors shared insights and advice ahead of the audience being invited to vote on a series of Summit resolutions intended to provide answers. The resolutions included time-bound goals, assignment of responsibilities for their delivery, and a publicly available toolkit to support their implementation. Please visit here for further information.
Important reference was made during the session to the ECCO Essential Requirements for Quality Cancer Care (ERQCCs) as well as the activities of the Innovative Partnership on Action against Cancer (iPAAC) in respect to improving governance of cancer care.
Dr Alberto Costa (Session Co-Chair)
European School of Oncology, Italy
Geoffrey Henning (Session Co-Chair)
Europacolon
View Presentation
Prof Gunnar Saeter
OECI
View Presentation
Dr Luciana Neamtiu
European Commission, Belgium
View Presentation
Ellen Griesshammer
German Cancer Society, Germany
View Presentation
Dr Reg Waldeck
Oncology Market Access Strategy Leader, Bayer, USA
View Presentation
|
15:00 - 15:30
|
Coffee Break |
15:30 - 17:30
|
Access and Value: It's about the entire cancer pathway
|
|
NEW HORIZON SESSION |
|
Led by Professor Yolande Lievens (Past-President, ESTRO), ECCO brought together a core group of experts to identify and reflect on existing methodologies for assessing value in respect to new pharmaceutical treatments. Following critical evaluation of the scales, including points of commonality and difference, the group shared their initial reflections and recommendations about the application of value based healthcare principles more holistically, including, but not limited to, non-systemic oncology treatments such as surgery and radiotherapy.
The existing value frameworks used in the oncology setting that have been assessed by the project include the ASCO Value Framework, the ESMO Magnitude of Clinical Benefit Scale and the NCCN Evidence Blocks.
The session will share the initial reflections on these value scales and invite wider stakeholder and audience contribution to the debate ahead of commencing a further stage of the project, which may include fuller articulation of a value scale that can translate for use in non-systemic oncology treatments.
The session provided opportunity for more general consideration of the value based healthcare agenda, its progression so far, policy learning from experiences of its application in different countries and settings, and desirable developments for the future.
Prof Richard Sullivan (Session Chair)
Prof Philip Poortmans (Concluding Remarks)
Prof Yolande Lievens
Past President of the European Society for Radiotherapy and Oncology (ESTRO)
View Presentation
Prof Riccardo Audisio
Past President of the European Society of Surgical Oncology (ESSO)
View Presentation
Dr Ajay Aggarwal
Institute of Cancer Policy, King’s College London
View Presentation
Kathy Oliver
International Brain Tumour Alliance, UK
View Presentation
Nicole Denjoy
COCIR
View Presentation
Vanessa Schaub
F. Hoffmann-La Roche, Switzerland
View Presentation
Part 2 of the session examined how the role of professional care to cancer patients, and other interventions, can be better valued and recognised within national health systems.
Dr Carole Farrell
European Oncology Nursing Society (EONS)
View Presentation
Prof Lorenzo Derchi
President of the European Society of Radiology
View Presentation
Dr Maria Die Trill
President of the International Psycho-Oncology Society (IPOS)
View Presentation
|
17:30 - 17:45
|
Coffee Break
|
17:45 - 19:15
|
Putting a price on cancer medicines: the challenges and prospective solutions
|
|
DEBATE SESSION |
|
The good news? Scientific advances are bringing forward new hope for cancer patients through emerging novel forms of treatment such as immunotherapy, targeted therapy and precision medicine. The bad news? Countries around the world continue to struggle with the headache of how to meet their cost.
This Summit session invited a range of stakeholders to spell out the top challenges in the current pharmaceutical pricing and access environment, presenting concrete proposals for improvement.
Summit attendees voted to record their preferences and responses to the proposals made.
Session chair: Dr Ian Banks
Eveline Scheres
Chair of the ECL Access to Cancer Medicines Taskforce
View Presentation
Nathalie Moll
Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
View Presentation
|
20:00 - 22:30
|
Networking Dinner at Festival Hall at the City Hall, Vienna
Entrance Lichtenfelgasse 2
Feststiege 1, 1010 Vienna
|
|
|
Sunday 9 September 2018
|
|
|
09:00 - 10:30
|
Survivorship: The next frontier of cancer care improvement
|
|
RESOLUTION-FORMING SESSION
|
|
The ECCO 2018 European Cancer Summit session on Survivorship built upon the important policy leadership activity of ECCO member EORTC in this area, including its biennial Survivorship Summit.
Hearing from cancer survivors, legal experts and academics, the session:
- paid particular attention to the matter of financial discrimination encountered by cancer survivors,
- highlighted available means of policy redress, such as the French Government’s enactment of legal reforms to enshrine a ‘right to be forgotten’ for cancer patients in respect to what they are obliged to declare to loan providers and insurers
- encouraged the expression by stakeholders of consensus ambitions for reducing financial discrimination encountered by cancer survivors across all European countries. More information here: https://www.eccosummit.eu/Resolutions/Survivorship-Financial-Discrimination
Prof Françoise Meunier (Session Chair)
EORTC, Belgium
View Presentation
Dr Marie Mesnil
University of Rennes, France
View Presenation
Janette Rawlinson
Cancer survivor and Patient Advocate, UK
View Presentation
Assigned interventions from
Carina Schneider
Childhood Cancer International Europe (CCI-Europe)
Alex Filicevas
European Cancer Patient Coalition (ECPC)
|
|
|
10:30-11:30
|
Patrick Johnston Memorial Lecture
Prof Françoise Meunier
EORTC, Belgium
View Presentation
|
11:30
|
Close of the Summit
|
11:30-12.00
|
Refreshment |